

1 **Variant Creutzfeldt-Jakob Disease: The Challenge of Preventing a Rare but Potentially**
2 **Devastating Exposure**

3 Ritambhara Pandey MD, Devesh Rai MD, Julie Giles NP, Maryrose Laguio-Vila MD, Emil
4 Lesho DO
5 Rochester Regional Health, Rochester, NY, USA

6

7

8 **Abstract**

9 Although rare, patients with variant Creutzfeldt-Jakob Disease (vCJD) in their differential
10 diagnosis of progressive dementia and movement disorder could continue to present to hospitals
11 for care. However, U.S.-based infection control guidelines do not fully address the possibility of
12 vCJD. After near-misses involving increasing numbers of patients with clinical findings and
13 epidemiologic risks compatible with vCJD, or exposures to chronic wasting disease, we sought
14 to improve recognition and prevention of iatrogenic spread of these prion-related diseases.

15

16

17

18

19

20

21 **Introduction**

22 Transmissible spongiform encephalopathies (TSEs) are progressively fatal
23 neurodegenerative diseases caused by infectious, misshapen prion proteins (PrP^{Sc}). In humans,
24 they include variant and classic (or sporadic) Creutzfeldt-Jakob Disease (vCJD/sCJD), the latter
25 being far more common in the U.S. Animal forms of prion disease include bovine spongiform
26 encephalopathy (BSE) and chronic wasting disease in cervids and some rodents.

27 TSEs present substantial diagnostic, infection control, and patient notification challenges
28 detailed in the discussion section below. Because prions resist usual standard disinfection and
29 sterilization protocols, iatrogenic exposures can occur via contaminated instruments or
30 equipment. Iatrogenic TSE can also be transmitted by percutaneous exposure to certain types of
31 tissue (mostly neural for sCJD), while vCJD can also be transmitted by exposure to infected
32 lymphoid tissue and possibly blood transfusions. This is why people from regions where BSE
33 was prevalent are still precluded from donating blood.¹⁻³

34 However, U.S.-based cleaning and disinfection and control guidelines and updates do not
35 address the possibility of vCJD.^{4,5} One of the reasons it is not included in general procedures is
36 that it is a rare occurrence and a special consideration. vCJD involves separate procedures that
37 are not applied across all reprocessing procedures, and different types of tissue that are
38 potentially infectious (not only neural).

39 Those guidelines do, however, recommend heightened awareness and policy
40 modification as events dictate.^{4,5} Additionally, experts have noted persistent risk of TSEs other
41 than sCJD in unsuspected geographic locations and a need for heightened suspicion and
42 surveillance.^{6,7} Furthermore, surveys of lymphoid tissue where PrP^{Sc} is found in cases of vCJD,

43 suggest the prevalence of asymptomatic disease can be as high as 1 in 2,000 in persons born
44 between 1941 and 1985.⁸

45 Two Illustrative Incidents

46 Two incidents typified the challenges we faced in caring for these and similar patients
47 and provided the impetus for this approach. The first incident involved a patient who presented
48 with memory problems, apathy and depression leading to job loss. These symptoms were
49 followed by confusion, impaired gait, occasional jerking movements and eventually dementia.
50 The patient lived in England and France from 1985 to 1993 and ate canned dog food
51 occasionally. The patient also required urgent pelvic and abdominal surgery immediately after
52 admission. MRI showed restricted diffusion in the frontal, parietal, and occipital cortexes. 14-3-
53 3, and Tau protein were negative. Since immune mediated encephalitis was also a leading
54 consideration on the list of possible diagnoses, the patient underwent plasma exchange. 13 days
55 later, the RTQuIC result became available and was positive. Contact tracing revealed that in the
56 meantime, three other patients had undergone pheresis on the same machine. The Red Cross was
57 contacted and recommended decommissioning the machine until further notice. The dilemma of
58 patient notification was debated by the ethics, risk management, infection control team and the
59 hospital leaders (Table 1).

60 The second incident involved a middle-aged patient who presented with psychiatric
61 symptoms and cognitive decline. The patient, who was an avid hunter and consumed venison
62 and squirrel brains, also developed impaired gait. An MRI showed bilateral pulvinar signs. The
63 EEG did not reveal periodic sharp waves, but showed nonspecific abnormalities including
64 intermittent rhythmic delta activity. The patient required several diagnostic and therapeutic
65 procedures including endoscopies and endotracheal intubation that entailed exposure to

66 lymphoid tissue. Approximately 2 weeks after admission, 14-3-3, Tau protein, and RTQuIC
67 results became available and were positive, creating a dilemma for reprocessing critical and
68 semi-critical equipment. After several months in the hospital, the patient was discharged to a
69 long-term care facility, and died more than 11 months after symptom onset. vCJD could not be
70 definitively excluded until autopsy results became available several months later and revealed
71 sCJD.

72 Against this backdrop, we sought to enhance our efforts to detect and prevent iatrogenic
73 spread of TSE, including vCJD. We also aimed to increase awareness among all providers,
74 prevent over-reaction or unnecessarily discarding expensive equipment, while simultaneously
75 not missing an opportunity to prevent avoidable exposures.

76 **Methods**

77 Rochester Regional Health System consists of 8 hospitals and 9 urgent care centers in St
78 Lawrence County, and the 9 counties comprising the Finger Lakes region of NY. The system
79 serves diverse populations including refugee communities and permanent or temporarily
80 relocated citizens or expatriates from many countries. In 2018, requests for CSF analysis for
81 suspected TSE increased 20% compared to the preceding four years.

82 The two-part intervention consisted of an educational campaign nearly identical to the
83 one successfully used for device-related infections and described previously.⁹ The second
84 component entailed an extensive revision of our existing CJD policy, incorporating
85 guidelines from the UK Department of Health and Social Care Advisory Committee and the
86 World Health Organization regarding vCJD.^{10, 11} Briefly, the educational campaign included one-
87 on-one engagements between infection preventionists (IPs), the hospital epidemiologist, the
88 neurologist champion and frontline nurses and providers. Modes of delivery included individual

89 face-to-face meetings, team huddles, committee meetings, group lectures and grand rounds.

90 Relevant guidelines were posted on hospital websites and intranet.

91 One goal of the policy revision was early notification of all teams involved in the care
92 including physicians, nursing staff including laboratory and sterile processing. Another goal was
93 a simplified classification scheme of potentially infected tissue. Tissues were divided into three
94 categories depending on their risk of infectivity: high, low, and no detectable infectivity (Table
95 2). Only single use or disposable instruments are recommended for suspected cases who undergo
96 surgery or invasive procedures involving contact with other than “no-risk” tissues. Non-
97 disposable instruments or durable medical equipment that contact other than no risk tissues
98 should be quarantined for possible decommissioning with appropriate labeling. All instruments
99 are considered potentially contaminated when used on patients with conditions not clearly
100 diagnosed before the procedure, and those instruments are either reprocessed according to prior
101 guidelines or quarantined until the diagnosis is confirmed.

102 **Results**

103 During the 2-year follow up period, there were no similar incidents or other near misses.
104 In response to queries from other IPs and epidemiologists, the policy was shared with hospitals
105 outside of the network. Feedback was uniformly positive.

106 **Discussion**

107 TSEs present diagnostic, infection control and patient notification challenges. Most
108 clinicians are unfamiliar with TSEs due to the rarity of those diseases. vCJD and CJD can be
109 hard to distinguish clinically. No gold standard laboratory test exists for differentiating types of
110 TSEs. The turn-around-time for RT-QiC can be up to 14 days or longer. In some cases, definitive

111 diagnosis requires brain biopsy or only becomes available after autopsy. Last, the National Prion
112 Center typically only releases autopsy results to public health departments, furthering diagnostic
113 delay.

114 This approach could be criticized for not being warranted or justifiable due to the fact
115 vCJD is extraordinarily uncommon. Even though sCJD is far more common than vCJD in the
116 U.S., patients with suspected vCJD have been increasingly encountered in our health system.
117 The suspicion was based on epidemiologic exposures and symptoms or signs consistent with
118 vCJD. For example, having lived in the United Kingdom or France for several years or decades,
119 or occupational exposure as taxidermists or abattoirs, or regular consumption of animal brains or
120 cervid meat products. Furthermore, available data indicate that the incidence of CJD in cervids
121 is increasing, and the potential exists for transmission to humans and subsequent human disease,
122 and the species barrier is not static.⁷ These occurrences are unlikely to be unique to our
123 healthcare system. To that end, we make our policy to those interested. It is available from the
124 corresponding author upon request.

125

126 Acknowledgements: None

127 Funding: There was no funding.

128 Conflicts of Interest: There are no conflicts of interest.

129

130

131

132 **References:**

- 133 1. American Red Cross. Eligibility reference material.
134 [https://www.redcrossblood.org/donate-blood/how-to-donate/eligibility-](https://www.redcrossblood.org/donate-blood/how-to-donate/eligibility-requirements/eligibility-criteria-alphabetical/eligibility-reference-material.html)
135 [requirements/eligibility-criteria-alphabetical/eligibility-reference-material.html](https://www.redcrossblood.org/donate-blood/how-to-donate/eligibility-requirements/eligibility-criteria-alphabetical/eligibility-reference-material.html).
136 Accessed January 19, 2021.
- 137 2. Belay ED, Schonberger LB. The public health impact of prion diseases. *Annu Rev*
138 *Public Health*. 2005;26:191-212.
- 139 3. Ricketts MN, Cashman NR, Stratton EE, El Saadany S. Is Creutzfeldt-Jakob disease
140 transmitted in blood? *Emerg Infect Dis*. 1997;3(2):155-163.
- 141 4. Rutala WA, Weber DJ. Creutzfeldt-Jakob disease: recommendations for disinfection
142 and sterilization. *Clin Infect Dis*. 2001;32(9):1348-1356.
- 143 5. Rutala WA, Weber DJ; Society for Healthcare Epidemiology of America. Guideline
144 for disinfection and sterilization of prion-contaminated medical instruments. *Infect*
145 *Control Hosp Epidemiol*. 2010;3(2)1:107-117.
- 146 6. Maheshwari A, Fischer M, Gambetti P, et al. Recent US case of variant Creutzfeldt-
147 Jakob Disease - global implications. *Emerg Infect Di.s* 2015;21(5):50-759.
- 148 7. Osterholm MT, Anderson CJ, Zabel MD, Scheftel JM, Moore KA, Appleby BS.
149 Chronic wasting disease in cervids: implications for prion transmission to humans
150 and other animal species. *mBio*. 2019;10(4):e01091-19.
- 151 8. Diack AB, Will RG, Manson JC. Public health risks from subclinical variant CJD.
152 *PLoS Pathog*. 2017;13(11):e1006642.
- 153 9. Lesho EP, Clifford R, Vore K, et al. Sustainably reducing device utilization and
154 device-related infections with DeCATHlons, device alternatives, and decision
155 support. *Infect Control Hosp Epidemiol*. 2020;41(11):1344-1347.

- 156 10. Advisory Committee on Dangerous Pathogens TSE Subgroup. ACDP's August 2016
157 Updated position statement on occurrence of vCJD and prevalence of infection in the
158 UK. [https://www.gov.uk/government/groups/advisory-committee-on-dangerous-](https://www.gov.uk/government/groups/advisory-committee-on-dangerous-pathogens)
159 pathogens. Accessed March 14, 2021
- 160 11. World Health Organization. WHO infection control guidelines for transmissible
161 spongiform encephalopathies. Report of a WHO consultation, Geneva, Switzerland,
162 23-26 March 1999.
163 [https://www.who.int/csr/resources/publications/bse/WHO_CDS_CSRAPH_2000_3/](https://www.who.int/csr/resources/publications/bse/WHO_CDS_CSRAPH_2000_3/en/)
164 en/. Accessed March 14, 2021.
- 165
166
167
168
169
170
171
172
173
174
175

176 **Table 1: Diagnostic, Infection Control, and Notification Challenges Associated with**
 177 **Transmissible Spongiform Encephalopathies**

Diagnostic Challenge
Most clinicians are unfamiliar with TSEs due to the rarity of those diseases.
vCJD and CJD can be hard to distinguish clinically.
No gold standard laboratory test exists for differentiating types of TSEs.
Turn-around-time for RT-QiC can be up to 14 days or longer.
In some cases, definitive diagnosis requires brain biopsy or only becomes available after autopsy.
The National Prion Center typically only releases autopsy results to public health departments, furthering delay.
Infection Control Challenges
Prions resist usual disinfection and sterilization methods.
US-based disinfection and sterilization guidelines do not address possibility of vCJD contaminated equipment.
Notification Challenges or Considerations
Should potentially exposed patients be informed given the below considerations?
i. Potential negative impact of informing patients about a fatal, untreatable brain disease.
ii. No effective screening test is available for TSE.
iii. No post exposure prophylaxis is available.
iv. Contaminated instruments often become mixed during re-processing making identification and linkage to specific patients nearly impossible.
v. Autoclaving is generally superior to chemical reprocessing for prions.
vi. If equipment was re-processed more than twice, prions would be less likely to survive.

178 **Table 2: Infectivity of Specific Types of Tissue**

	Classic/ Sporadic CJD	Variant CJD
High Infectivity Tissue NO Reprocessing Allowed*	Brain (including dura mater) Spinal cord Posterior eye Pituitary tissue	Brain (including dura mater) Spinal cord, spinal ganglia Posterior eye Pituitary tissue Trigeminal ganglia
Low Infectivity Tissue NO Reprocessing Allowed*	Cerebrospinal fluid (CSF) Liver Lymph node Kidney Lung (Bronchoscope) Spleen Placenta Olfactory epithelium	Adrenal gland Blood Tonsils (Laryngoscope) Cerebrospinal fluid (CSF) Intestine (Endoscope) Bone marrow Liver Lymph node Kidney Lung (Bronchoscope) Spleen Skeletal muscle Placenta Olfactory epithelium Peripheral Nerves Rectum (Endoscope)
Tissue with no detectable infectivity OK to Reprocess*	Peripheral nerve Intestine Bone marrow Whole blood, leukocytes, serum, plasma Thyroid gland Adrenal gland Heart Skeletal muscle Adipose tissue Gingiva Prostate and testis Tears, sweat, saliva, and sputum Urine, and feces Semen, vaginal secretions, Milk	Thyroid gland Heart Adipose tissue Gingiva Prostate and testis Tears, sweat, saliva, and sputum Urine, and feces Semen, vaginal secretions, Breast milk

180 *Applies to surgical instruments and certain invasive equipment such as endoscopes and
181 laryngoscope blades
182